HER-2 pulsed DC1

BIOLOGICAL2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute

Conditions

Breast CancerHER2-positive Breast Cancer

Phase 1

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

WithdrawnNCT02336984

H. Lee Moffitt Cancer Center and Research InstituteBreast Cancer

Start: 2014-06-30End: 2016-04-04Updated: 2021-01-11

Phase 2

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

RecruitingNCT05325632

H. Lee Moffitt Cancer Center and Research InstituteHER2-positive Breast Cancer

Start: 2021-10-28End: 2027-09-01Target: 53Updated: 2026-03-02

Related Papers

Intratumoral dendritic cell (DC1) therapy prior to neoadjuvant chemotherapy in HER2-positive breast cancer (NATASHA trial).

Journal of Clinical Oncology2026-05-27

Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.

2026-05-13

A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer

npj Breast Cancer2025-03-175 citations

Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in <i>ERBB2</i> Breast Cancer

JAMA Oncology2024-12-053 citations

A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).

Journal of Clinical Oncology2024-06-011 citations

Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.

Journal of Clinical Oncology2023-06-011 citations